In addition, although the cross-sectional nature of the present study does not allow cause-to-effect relationships, it may be speculated that the abnormally low levels of FGF19 in GDM patients contribute to metabolic disturbances such as hyperglycemia and insulin resistance that occur commonly in these patients. This evidence concerns the gene FGF19 and Insulin resistance.